Wound healing modulation after glaucoma surgery.
Recent developments in molecular and cell biology have made a major impact on our understanding of the wound healing process and its modification. In this article, the spectrum of therapies that are either currently available or have potential application as modulators of the scarring response following glaucoma surgery are reviewed. Refinement of existing antimetabolite regimens can improve surgical results, especially in carefully selected patient groups. However, the most promising new approach appears to be using molecular-based therapies, such as fully human neutralizing monoclonal antibodies, designed to target specific molecules in the scarring response. Such strategies ultimately offer the potential of safer, more specific, focal, and titratable treatment, with far-reaching clinical applications.
Cordeiro
M F
MF
Department of Pathology, Moorfields Eye Hospital, London, UK.
Siriwardena
D
D
Chang
L
L
Khaw
P T
PT
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D018463:Filtering Surgery; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D011183:Postoperative Complications / Q000188:drug therapy / Q000473:pathology*; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology*
D000893:Anti-Inflammatory Agents; D005343:Fibrinolytic Agents